The application and diagnostic utility of immunocytochemistry on direct smears in the diagnosis of pulmonary adenocarcinoma and squamous cell carcinoma

Diagnostic Cytopathology

Volumn 40, Issue 11, 2012, Pages 949-955

  Roh, Michael H ^a   Schmidt, Lindsay ^a   Placido, Jeremiah ^a   Farmen, Sara ^a   Fields, Kristina L ^a   Courey, Anthony J ^a   Arenberg, Douglas A ^a   Knoepp, Stewart M ^a  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

cytology; lung cancer; napsin A; p63; TTF 1

Indexed keywords

NAPSIN A; PROTEIN P63; THYROID TRANSCRIPTION FACTOR 1; TUMOR PROTEIN; UNCLASSIFIED DRUG;

ARTICLE; CLINICAL ARTICLE; CYTOLOGY; ENDOBRONCHIAL ULTRASONOGRAPHY; HUMAN; HUMAN TISSUE; IMMUNOCYTOCHEMISTRY; IMMUNOHISTOCHEMISTRY; IMMUNOPHENOTYPING; LUNG ADENOCARCINOMA; LUNG BIOPSY; LUNG SQUAMOUS CELL CARCINOMA; PLEURA EFFUSION; PRIORITY JOURNAL; TISSUE MICROARRAY; TRANSBRONCHIAL ASPIRATION;

ADENOCARCINOMA; ASPARTIC ACID ENDOPEPTIDASES; CARCINOMA, SQUAMOUS CELL; DNA-BINDING PROTEINS; ENDOSCOPIC ULTRASOUND-GUIDED FINE NEEDLE ASPIRATION; HUMANS; IMMUNOHISTOCHEMISTRY; IMMUNOPHENOTYPING; LUNG; LUNG NEOPLASMS; MEMBRANE PROTEINS; PLEURAL EFFUSION; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; TISSUE ARRAY ANALYSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 84865983277     PISSN: 87551039     EISSN: 10970339     Source Type: Journal    
DOI: 10.1002/dc.21680     Document Type: Article

References (23)

1. Travis WD, World Health Organization, International Agency for Research on Cancer. International Association for the Study of Lung Cancer, International Academy of Pathology. 2004. Pathology and Genetics of Tumors of the Lung, Pleura, Thymus, and Heart. Lyon: IARC Press; 344 p.
2. Ladanyi M, Pao W,. Lung adenocarcinoma: Guiding EGFR-targeted therapy and beyond. Mod Pathol 2008; 21 (Suppl 2): S16-S22.
3. Travis WD,. Pathology of lung cancer. Clin Chest Med 2002; 23: 65-81.
4. Besse B, Ropert S, Soria JC,. Targeted therapies in lung cancer. Ann Oncol 2007; 18 (Suppl 9): ix135-ix142.
5. Herbst RS,. Toxicities of antiangiogenic therapy in non-small-cell lung cancer. Clin Lung Cancer 2006; 8 (Suppl 1): S23-S30.
6. Johnson DH, Fehrenbacher L, Novotny WF, et al. Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol 2004; 22: 2184-2191.
7. Scagliotti GV, Parikh P, von Pawel J, et al. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol 2008; 26: 3543-3551.
8. Mukhopadhyay S, Katzenstein AL,. Subclassification of non-small cell lung carcinomas lacking morphologic differentiation on biopsy specimens: Utility of an immunohistochemical panel containing TTF-1, napsin A, p63, and CK5/6. Am J Surg Pathol 2011; 35: 15-25.
9. Rekhtman N, Brandt SM, Sigel CS, et al. Suitability of thoracic cytology for new therapeutic paradigms in non-small cell lung carcinoma: High accuracy of tumor subtyping and feasibility of EGFR and KRAS molecular testing. J Thorac Oncol 2011; 6: 451-458.
10. Lau SK, Luthringer DJ, Eisen RN,. Thyroid transcription factor-1: A review. Appl Immunohistochem Mol Morphol 2002; 10: 97-102.
11. Jagirdar J,. Application of immunohistochemistry to the diagnosis of primary and metastatic carcinoma to the lung. Arch Pathol Laboratory Med 2008; 132: 384-396.
12. Hirano T, Gong Y, Yoshida K, et al. Usefulness of TA02 (napsin A) to distinguish primary lung adenocarcinoma from metastatic lung adenocarcinoma. Lung Cancer 2003; 41: 155-162.
13. Chuman Y, Bergman A, Ueno T, et al. Napsin A, a member of the aspartic protease family, is abundantly expressed in normal lung and kidney tissue and is expressed in lung adenocarcinomas. FEBS Lett 1999; 462: 129-134.
14. Suzuki A, Shijubo N, Yamada G, et al. Napsin A is useful to distinguish primary lung adenocarcinoma from adenocarcinomas of other organs. Pathol Res Pract 2005; 201: 579-586.
15. Yang M, Nonaka D,. A study of immunohistochemical differential expression in pulmonary and mammary carcinomas. Mod Pathol 2010; 23: 654-661.
16. Dejmek A, Naucler P, Smedjeback A, et al. Napsin A (TA02) is a useful alternative to thyroid transcription factor-1 (TTF-1) for the identification of pulmonary adenocarcinoma cells in pleural effusions. Diagn Cytopathol 2007; 35: 493-497.
17. Stoll LM, Johnson MW, Gabrielson E, et al. The utility of napsin-A in the identification of primary and metastatic lung adenocarcinoma among cytologically poorly differentiated carcinomas. Cancer Cytopathol 2010; 118: 441-449.
18. Terry J, Leung S, Laskin J, et al. Optimal immunohistochemical markers for distinguishing lung adenocarcinomas from squamous cell carcinomas in small tumor samples. Am J Surg Pathol 2010; 34: 1805-1811.
19. Ou SH, Zell JA,. Carcinoma NOS is a common histologic diagnosis and is increasing in proportion among non-small cell lung cancer histologies. J Thorac Oncol 2009; 4: 1202-1211.
20. Khayyata S, Yun S, Pasha T, et al. Value of P63 and CK5/6 in distinguishing squamous cell carcinoma from adenocarcinoma in lung fine-needle aspiration specimens. Diagn Cytopathol 2009; 37: 178-183.
21. Abendroth CS, Dabbs DJ,. Immunocytochemical staining of unstained versus previously stained cytologic preparations. Acta Cytol 1995; 39: 379-386.
22. Bishop JA, Sharma R, Illei PB,. Napsin A and thyroid transcription factor-1 expression in carcinomas of the lung, breast, pancreas, colon, kidney, thyroid, and malignant mesothelioma. Hum Pathol 2010; 41: 20-25.
23. Au NH, Gown AM, Cheang M, et al. P63 expression in lung carcinoma: a tissue microarray study of 408 cases. Appl Immunohistochem Mol Morphol 2004; 12: 240-247.